We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Aoxing Pharmaceutical Company New (delisted) | AMEX:AXN | AMEX | Ordinary Share |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.1218 | 0.00 | 00:00:00 |
From Nov 2019 to Nov 2024
NEW YORK, Dec. 2, 2015 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aoxing Pharmaceutical, Inc. ("Aoxing" or the "Company") (NYSE MKT: AXN). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
The investigation concerns whether Aoxing and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On December 1, 2015, post-market, Aoxing reported the resignation of Wilfred Chow, the Company's Chief Financial Officer, on November 30, 2015. On this news, Aoxing shares fell $0.07, or 5.11%, to close at $1.30 on December 2, 2015.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-aoxing-pharmaceutical-inc--axn-300187342.html
SOURCE Pomerantz LLP
Copyright 2015 PR Newswire
1 Year Aoxing Pharmaceutical Company New (delisted) Chart |
1 Month Aoxing Pharmaceutical Company New (delisted) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions